Page 22 - KCMSQ315

ATUREKCHDKENT COUNTY HEALTH DEPARTMENT CONTINUED FROM PAGE 21FindingsBetween April 1 and July 20, 2015, 90 clusters, with a total population of 7,561 people were included in the study. Forty-eight (48) of the clusters (4,123 people) were assigned immediate vaccination and 42 clusters (3,528 people) were assigned delayed vaccine. In the immediate vaccination group, no individuals met the primary outcome criteria compared to 16 individuals in the delayed vaccination group (from 7 clusters), resulting in a vaccine efficacy of 100% (95% CI 74.7% - 100%; p=0.0036). At the cluster level, with the inclusion of all eligible results, vaccine effectiveness was 75.1% (95% CI -7.1% - 94.2%). It must be noted that 9 cases of EBV occurred in the immediate vaccination group and 16 cases occurred in the delayed vaccination group within the 10 days after vaccination. The authors note, however, that no new cases of EBV were diagnosed in either group more than 6 days after vaccination.Among vaccine recipients, 43 serious adverse events were reported with only one judged to be causally related to vaccination (a febrile episode that resolved without sequelae). ToRead MoreThe full version of this article can be found at http://www.thelancet.com/pb/assets/raw/ Lancet/pdfs/S0140673615611175.pdfassess adverse events, those vaccinated were observed for 30 minutes post-vaccination and were visited at home on days 3, 14, 21, 42, 63 and 84 post-vaccination.ImplicationsThe results of this interim analysis shows promise that rVSV-ZEBOV might be highly effective in preventing EBV and is most likely effective at the population level when delivered during an outbreak as post-exposure treatment of individuals at high risk of infection (ring vaccination). Despite the fact that the incidence of EBV is decreasing in the countries of West Africa, these results offer a ray of hope in the fight against a deadly disease that has ravaged nations and sent ripples of fear across the globe.22 KCMS/KCOA BULLETINSUMMER 2015